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Background: Tumor but not normal cells frequently overexpress heat shock protein 70 (Hsp70) and present it on
their cell surface (mHsp70) from where it can be actively released. Therefore, membrane (mHsp70) and soluble
Hsp70 (sHsp70) were investigated as potential tumor biomarkers and for monitoring the outcome of radiation
therapy.
Methods: Biopsies and blood were collected from patients with squamous cell carcinoma of the head and neck
(SCCHN) at different time points (before, during therapy and in the follow-up period). Hsp70 membrane expression
was determined on single cell suspensions of tumor biopsies and reference tissues by flow cytometry, sHsp70
protein and antibody levels were determined in the serum of patients and healthy donors by ELISA and NK
cell markers that are related to the presence of sHsp70 were analyzed in the patient’s peripheral blood
lymphocytes (PBL).
Results: Tumor biopsies exhibited significantly increased mHsp70 expression levels compared to the reference
tissue. Soluble Hsp70 levels were significantly higher in SCCHN patients compared to healthy human volunteers
and high mHsp70 expression levels on tumor cells were associated with high sHsp70 levels in the serum of
patients. Following surgery and radiotherapy sHsp70 levels in patients dropped in patients without tumor relapse in
the follow-up period. In contrast to sHsp70 protein, anti-Hsp70 antibody levels remained nearly unaltered in the
serum of SCCHN patients before and after therapy. Furthermore, sHsp70 protein but not anti-Hsp70 antibody levels
were found to be associated with the tumor volume in SCCHN patients before start of therapy. The expression
densities of the activatory NK cell markers CD56, CD94, NKG2D, NKp30, Nkp44, and NKp46 differed in patients
following therapeutic intervention. A significant increase in the density of NKG2D was observed in SCCHN patients
in the follow-up period after surgery and radiotherapy.
Conclusion: We suggest sHsp70 as a potential biomarker for detecting tumors and for monitoring the clinical
outcome of radiotherapy in SCCHN patients.
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Table 1 Age and gender of SCCHN patients and healthy
human volunteers
Healthy controls SCCHN patients
Number (n) 28 21
Gender (M/F) 12/16 20/1
Age Mean (Range) 61.0 (47–74) 66.7 (38–78)
SD 7.0 9.2
Median 61.5 66.0
Abbreviations: M male, F female, SD standard deviation, SCCHN Squamous Cell
Carcinoma of the Head and Neck.
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Biomarkers are getting more and more important for a
better prognosis and for and improved follow-up of a
therapy as recently shown for gastro-intestinal tumors
[1,2]. Optimal biomarkers should be presented on the
cell surface of a broad variety of tumor cells but not on
normal cells and should be released in a tumor-specific
manner. In order to use biomarkers for the prediction of
outcome it is important that the biomarkers remain
stable during therapeutic intervention. The presence of
biomarkers in the urine or blood of a patient allows re-
peated tests with a minimal invasive intervention.
For a long time heat shock proteins including Hsp70
and auto-antibodies directed against them have been
shown to provide useful biomarkers for the prediction of
prostate cancer [3] and squamous cell carcinoma of the
oesophagus [4]. Elevated heat shock protein levels have
been detected in many different types of cancer [5].
Nevertheless, the approaches have not been validated
sufficiently and thus are yet not in clinical use. Hsp70
the major stress-inducible member of the HSP70 family
has the potential for being a predictive marker molecule
for several reasons. Hsp70 is overexpressed in many
different tumor types; it is protecting cells from DNA
damage [6], and exerts anti-apoptotic functions [7]. Over-
expressed inside cells, Hsp70 is transported to the cell
membrane and also exported into the extracellular space
[8]. The transport routes are not following the classical
transport routes through the ER and Golgi apparatus but
instead are mediated through endosomal and lysosomal
vesicles [9]. Only a small proportion of Hsp70 is released
as free Hsp70 by necrotic cell death. Our findings demon-
strate that the majority of extracellular Hsp70 is bound to
small lipid vesicles [9]. Theses vesicles are actively released
by tumor cells presumably for signaling purposes. It al-
ready has been shown that released Hsp70 can stimulate
the adaptive immune system [10]. NK cells also recognize
Hsp70, bind it and thus can be activated [11]. Following
activation, NK cells actively migrate towards Hsp70 posi-
tive tumor cells, and kill them via the release of the cyto-
toxic enzyme granzyme B [12].
Extracellular Hsp70 can be detected by ELISA. Recent
results of our group show that Hsp70 can be detected in
the plasma of mice bearing human xenograft tumors [13].
Additionally, the plasma Hsp70 levels correlate with the
tumor burden of mice assuming the potential of Hsp70 as
predictive tumor marker.
Since Hsp70 can be released by human tumor cells
with a membrane Hsp70-positive phenotype, we studied
the diagnostic impact of sHsp70 in serum of patients
suffering from SCCHN. Serum levels of sHsp70 were
assessed in patients before and at different time points
after radiation therapy and compared to that of healthy
controls. In order to study the role of sHsp70 as apotential stimulator of NK cells we concomitantly stud-
ied the expression of activatory NK cell markers on the
PBL of the patients.
Patients and methods
Patients
In total, 21 (20 male, 1 female) patients suffering from
tumors localized in the oral cavity (5 cases), larynx (6),
oro/hypopharynx (2), oropharynx (7), sinus (1) and 28
age-matched healthy human volunteers were enrolled
into the study (Tables 1 and 2). The mean age of all
patients was 66.7 years (range 38–78) with a median of
66.0 years and that of healthy individuals was 61.0 (mean
47–74) with a mean of 61.5 years, respectively (Table 1).
The clinicopathological characteristics and the treatment
regime of each individual patient are summarized in
Table 2. Tumor volume was determined by manually
contouring the gross tumor volume (GTV) based on con-
trast enhanced computer tomography scans using iPlan
planning software (Brainlab, Feldkirchen, Germany). Total
radiation doses following tumor excision were 64 Gy (11
patients), and 60 Gy (2 patients), respectively. One patient
received a definitive radiation with a total dose of 70 Gy,
and 7 patients received no adjuvant radiation therapy fol-
lowing complete tumor resection. All patients and healthy
human individuals provided written informed consent for
the collection of blood and tumor biopsies which was ap-
proved by the Ethics Committee of the Klinikum rechts
der Isar der Technischen Universität München. Blood was
collected from untreated tumor patients before surgery
and adjuvant radiotherapy and at indicated time points
after tumor excision and radiotherapy by venepuncture.
9 ml EDTA-blood and 9 ml serum were collected in
S-Monovettes (Sarstedt, Nümbrecht, Germany).
Tumor biopsies
Biopsies in the size range of a few mm3 were taken du-
ring tumor excision. As a reference, connective tissues
derived from 7 tumor-free donors were collected. Single
cell suspensions from freshly isolated tumor biopsies
were isolated by mechanical disintegration and by for-
cing the cell suspension through a sterile mesh (75 μm)
Table 2 Clinicopathological characteristics of all SCCHN patients
Patient # Tumor location Stadium Grading Therapy
T N M Surgery RTx dose (Gy)
1 Oral cavity 2 2 cd 0 2 + 0
2 Larynx 4 2b 0 3 + 64
3 Oral Cavity 1 0 0 2 + 60
4 Oro/Hypopharynx 4 2a 0 2 + 64
5 Oropharynx 3 2 0 2 - 70
6 Oropharynx 1 2b 0 3 + 64
7 Oral Cavity 1 2a 0 2 + 64
8 Oro/Hypopharynx 1 0 0 2 + 64
9 Oral Cavity 1 0 0 2 + 64
10 Oral Cavity 1 0 0 3 + 0
11 Oropharynx 2 2a 0 2 + 0
12 Larynx 2 2b 0 3 + 0
13 Oropharynx 4 0 0 2 + 64
14 Oropharynx 2 0 0 3 + 64
15 Larynx 3 0 0 3 + 64
16 Larynx 4 1 0 3 + 0
17 Oropharynx 2 2b 0 3 + 0
18 Oropharynx 2 1 0 2 + 64
19 Larynx 2 1 0 2 + 64
20 Sinus 2 0 0 3 + 60
21 Larynx 4 0 0 3 + 0
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described previously [14].
Serum
Blood was centrifuged at 750 × g at room temperature
(RT) for 10 min the supernatant containing the serum
was removed, mixed, and stored at −80°C in aliquots.
Sera were used for experiments after thawing only once.
Control serum samples were collected from age-matched
healthy human volunteers (Table 1).
ELISA assays
Total sHsp70 levels in serum samples of humans were
measured using a modified Hsp70 immunoassay (Duoset,
DYC1663, R&D Systems, Minneapolis, MN, USA). The
ELISA is designed to detect human Hsp70 in buffer. All
serum samples were analyzed in three independent expe-
riments in duplicates.
Anti-Hsp70 antibodies in the serum were detected
using a sandwich ELISA. Briefly, Hsp70 protein (ADI-
NSP-555, Enzo Life Sciences, Farmingdale, NY, USA)
was coated onto MaxiSorp 96-well plates (NuncNalgene,
Thermo Fisher Scientific, Waltham, MA, USA). After in-
cubation with serum the bound antibodies were detec-
ted by incubation with HRP-conjugated anti-humanIg followed by HRP-substrate (DY999, R&D Systems,
Minneapolis, MN, USA).
Flow cytometry
Single cells from freshly isolated tumor biopsies were
prepared by mechanical disintegration of the tissue, as
described previously [14]. 1 × 105 cells were washed
once with 10% FCS in PBS and incubated with a FITC-
conjugated mouse monoclonal antibody specific for
membrane-bound Hsp70 (cmHsp70.1, IgG1, multimmune
GmbH, Munich, Germany) or a FITC-labeled isotype-
matched IgG1 negative control antibody (345815, BD
Biosciences, Franklin Lakes, NJ, USA) on ice in the
dark for 30 min. After washing, propidium iodide was
added and viable cells were analyzed on a FACSCali-
bur flow cytometer (BD Biosciences). The percentage
of cells stained with an isotype-matched control anti-
body was subtracted from the percentage of mHsp70
positive cells.
NK cell markers were determined in the peripheral
blood of the patients by flow cytometry as described previ-
ously [15]. After incubation with fluorescence-conjugated
antibodies (CD56, CD94, CD3, CD94, NKG2D, NKp30,
NKp44, NKp46), or the appropriate mouse isotype-
matched control antibodies, erythrocytes were lysed using
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manufacturer’s instructions. After washing, lymphocytes
were analyzed on a FACSCalibur flow cytometer (BD Bio-
sciences). The NK cells were gated according to their
CD56 positivity and CD3 negativity. The percentage of
cells stained with an isotype-matched control antibody
was subtracted from the percentage of antibody-positively
stained cells.
Statistical analysis
Statistical analysis was performed using SigmaPlot soft-
ware delivered by Systat Software Inc. (San Jose, CA,
USA). Results for the levels of mHsp70, sHsp70, or anti-
Hsp70 antibodies are presented as standard box plots
with boundaries indicating the 25th and the 75th percen-
tile. The line inside boxes indicates the median and the
whiskers indicate the 10th and 90th percentile, respect-
ively. All outliers are shown. The square of the coeffi-
cient of correlation parameter R2 and linear regression
analysis were used to determine the relationships be-
tween variables. For comparison between groups of data
the student’s t-test was used to evaluate differences. p-
values <0.05 were considered to be statistically significant.
Results
Hsp70 membrane expression on tumor biopsies of
SCCHN patients
Tumor biopsies were obtained from patients with SCCHN
by tumor resection (n = 21) and reference connective tis-
sues of tumor-free donors (n = 7). The Hsp70 membrane
status (mHsp70) was determined on viable single cell




























Figure 1 Hsp70 membrane expression on biopsies of SCCHN patients
antibody corrected with IgG1 isotype-matched control antibody are depict
into low (n = 10) and high (n = 11) mHsp70 expressing cells. Single cells fro
controls. B. Mean fluorescence intensity from the same data set as shown
and the 75th percentile. The line inside boxes indicates the median and the
are included into the graphs. (*p < 0.05, **p < 0.01, ***p < 0.001).cmHsp70.1 monoclonal antibody. The mean percent-
age of Hsp70 positive cells was significantly higher in
tumor patients compared to that of the tissue of 7 control
tissues which were prepared in parallel (mean 38% vs.
13%) (Figure 1A). The percentage of mHsp70 positive
cells in patient biopsies ranged between 5 to 100%. Ac-
cording to their Hsp70 membrane status, the results of
the patient samples could be divided into two subgroups.
The mean percentage of mHsp70 positive cells in the
group with a high Hsp70 expression (n = 11) was around
83% and that of the low Hsp70 expressing group (n = 1)
was 20% (Figure 1A, boxplots on the right hand side). The
mean fluorescence intensity values correlated with the
data of the percentage of Hsp70 membrane positive cells
(Figure 1B).
sHsp70 serum levels in patients with SCCHN
To address the question whether the membrane Hsp70
expression correlates with the soluble Hsp70 (sHsp70)
serum levels, sHsp70 levels were determined in serum of
SCCHN patients before start of any therapy. The mean
sHsp70 levels were significantly elevated in SCCHN
patients (5.3 ± 4.1 ng/ml, n = 21) compared to age-
matched healthy human volunteers (2.2 ± 0.6 ng/ml,
n = 28) (Figure 2A). Patients with tumors that exhibit a
high Hsp70 membrane (mHsp70) expression (Figure 1,
high) also exhibited higher sHsp70 serum levels (7.2 ±
6.7 ng/ml, n = 11) than patients with a low (Figure 1, low)
Hsp70 membrane expression (3.4 ± 1.2 ng/ml, n = 10)
(Figure 2B).
Receiver operating characteristic (ROC) curve analysis
























. A. The cells stained with FITC-labeled cmHsp70.1 monoclonal
ed in box plots. Data from patients’ tumor cells (n = 21) were divided
m healthy donors (n = 7) derived from connective tissues were used as
in A. Standard box plots are shown with boundaries indicating the 25th











































Figure 2 sHsp70 serum levels in blood of patients with SCCHN. A. sHsp70 concentrations in sera of patients (n = 21) before therapy
compared to healthy donors (n = 28). B. sHsp70 serum data from patients were separated into two groups (high n = 11, low n = 10) reflecting the
mHsp70 membrane expression as measured in A. C. Standard box plots are shown with boundaries indicating the 25th and the 75th percentile.
The line inside boxes indicates the median and the whiskers indicate the 10th and 90th percentile, respectively. All outliers are shown. (***p < 0.001)
C. ROC curve of data from (A) were attained by SigmaPlot software showing an AUC of 0.9101 (p < 0.0001, CI 95%). The cut-off level was 2.5 ng/ml with
a sensitivity of 89% and a specificity of 91%). Abbr.: ROC, receiver operating characteristic; AUC, area under the curve; CI, confidence interval.
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sHsp70 levels of healthy donors were compared to that
of SCCHN patients. The ROC curve reveals an area
under the curve (AUC) of 0.91 (p < 0.0001, CI 95%). This
means that the cut-off level was 2.5 ng/ml with a sensi-
tivity of 89% and with a specificity of 91% for sHsp70 as
a tumor biomarker.
Time-dependent alterations in sHsp70 and anti-Hsp70
antibody levels in the serum of SCCHN patients
An ideal tumor biomarker should be able to predict cli-
nical responses to therapy, such as radiation therapy or
surgery. Soluble Hsp70 levels were found to be signifi-
cantly elevated in tumor patients before therapy (5.3 ±
4.1 ng/ml, n = 21) compared to healthy donors (2.2 ±
0.6 ng/ml, n = 28). The levels remained elevated up to
6 weeks after tumor resection (7.0 ± 3.6 ng/ml, n = 10)
(Figure 3, during therapy). In the first and second follow-up year after radiotherapy sHsp70 levels dropped to 3.4 ±
1.4 ng/ml (n = 9) and 3.1 ± 1.1 ng/ml (n = 14), respectively
(Figure 3, follow-up 1st year, follow-up 2nd year).
The mean anti-Hsp70 antibody concentrations were
not significantly different in tumor patients before ther-
apy (122 ± 119 ng/ml, n = 16) and in healthy human vol-
unteers (84 ± 64 ng/ml), as shown in Figure 4. Also after
therapy (surgery/radiotherapy) the mean anti-Hsp70 an-
tibody concentrations in the serum did not change sig-
nificantly (140 ± 119 ng/ml, n = 6).
Correlation of sHsp70 protein and anti-Hsp70 antibody
levels with the tumor volume of the patients with SCCHN
To evaluate whether the serum levels of sHsp70 protein
or anti-Hsp70 antibodies correlate with tumor volumes,
the tumor volumes were determined by using CT images.
The tumor size in the cohort of SCCHN patients (n = 13)




























Figure 3 sHsp70 levels in the serum of SCCHN patients untreated and after therapy. Blood was collected from patients with SCCHN.
sHsp70 concentration was measured with ELISA in three independent experiments in duplicates. Standard box plots are shown with boundaries
indicating the 25th and the 75th percentile. The line inside boxes indicates the median and the whiskers indicate the 10th and 90th percentile,
respectively. All outliers are shown in the graph. (healthy n = 28, before therapy n = 21, during therapy n = 10, follow-up 1st year n = 9, follow-up 2nd
year n = 14). The reason for the different n numbers is due to some missing blood samples during the course of disease. (*p < 0.05, ***p < 0.001).




















Figure 4 Anti-Hsp70 antibody levels in the serum of patients
before, and at indicated time-points after radiation therapy.
Time course of anti-Hsp70 antibodies in the serum of patients with
SCCHN tumors before and after therapy. Blood was collected and
anti-Hsp70 antibodies were determined by anti-Hsp70 antibody
ELISA. Standard box plots are shown with boundaries indicating the
25th and the 75th percentile. The line inside boxes indicates the median
and the whiskers indicate the 10th and 90th percentile, respectively. All
outliers are shown in the graph. (healthy n = 4, patients before
therapy n = 16, patients after therapy at least 6 weeks after radiation
therapy n = 6).
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though not statistically significant, the detected serum
sHsp70 levels in patients with larger tumor volumes were
higher than in patients with smaller tumors (R2 = 0.6427)
(Figure 5A), whereas the anti-Hsp70 antibody levels
in the serum showed no association with the tumor vol-
ume (R2 = 0.1198) (Figure 5B).
Expression of activatory NK cell receptors on PBL of
SCCHN patients
In order to test the relevance of the sHsp70 with respect
to the stimulation of an NK cell mediated immune re-
sponse, the expression of activatory NK cell markers was
assessed in the blood samples of selected patients before
tumor excision and at indicated later time points after
radiotherapy. The expression density of the markers
CD56, CD94, NKp30, NKp44, and NKp46 varied in the
tested patients before, during therapy and within the
follow-up period (Figure 6A-F). With respect to the
receptor NKG2D, the expression density gradually in-
creased throughout the whole monitoring period in all pa-
tients (Figure 6C). A significant increase in the expression
density of NKG2D was observed in the blood of patients
before therapy (1) and after the second follow-up year (4)
(Figure 6G, n = 7).
tumor volume (ml)






































Figure 5 Correlation of tumor volume with Hsp70 protein and
anti-Hsp70 antibody serum levels in patients with SCCHN.
Tumor volumes were determined by manually contouring the gross
tumor volume (GTV) of patients based on contrast enhanced
computer tomography scans before radiation therapy. The assessed
tumor volumes in ml were associated with the sHsp70 serum
(A, n = 13) and anti-Hsp70 antibody (B, n = 10) levels as determined
by ELISA. Linear regression was determined by SigmaPlot
statistical software.
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Tumor biomarkers are useful tools for tumor detection
and for monitoring the clinical outcome. Instead of tu-
mor biopsies, which are difficult to obtain, blood sam-
ples that can be taken regularly by minimal invasive
methods qualify much better to measure clinical out-
come. Heat shock proteins are frequently overexpressed
in tumor cells and thus are reported as biomarkers [5],
in prostate [3], and in pancreatic carcinomas [16]. It also
has been shown previously that elevated Hsp70 levels
can act as a read-out for the efficacy of Hsp90 inhibitor-
based therapies [17]. Also autoantibodies directed against
Hsp70 in squamous cell carcinoma [4] are discussed as
potential biomarkers.As already demonstrated for other tumor entities [14]
also SCCHN tumors are frequently found to be Hsp70
membrane-positive (Figure 1). Furthermore, in our rela-
tively small cohort of 21 patients two subgroups could
be identified that differ in their Hsp70 membrane posi-
tivity. Eleven patients showed a high and ten patients a
low Hsp70 membrane expression. A longer follow-up
of the patients and the testing of a larger cohort of
patients will elucidate whether differences in the mem-
brane Hsp70 density has an impact on diagnosis or clin-
ical outcome. Furthermore, we could show that the
Hsp70 membrane expression on the tumor biopsy was
associated with increased sHsp70 serum levels (Figure 2).
Elevated sHsp70 levels were detectable up to six weeks
after tumor resection (Figure 3). A slight increase in
sHsp70 serum levels might be explained by sHsp70
which is released by dying cells during therapy. Within
the first and second year follow-up period the sHsp70
levels dropped significantly in patients who did not re-
lapse. In contrast to the sHsp70 protein the levels of
anti-Hsp70 antibodies were only slightly increased in
tumor patients compared to that of healthy individuals.
We could show that in a well-established FaDu xeno-
graft tumor mouse model of human SCCHN, sHsp70
concentrations correlated with the tumor volume even
in very small tumor sizes of ≈ 1 mm3 [13]. Therefore, we
speculate that sHsp70 levels might be useful in screening
tests that aim to detect cancer at early stages or in small
tumors or metastases also in humans. The FaDu xeno-
graft model is frequently used to investigate the outcome
of radiation therapy [18]. We could show that sHsp70
plasma levels were able to monitor local control of FaDu
tumors in mice after irradiation with 30 Gy [13]. There-
fore, a drop in serum sHsp70 levels might be able to pre-
dict the clinical outcome of radiotherapy in humans.
It has been shown that Hsp70 is actively released by
viable, intact tumor cells and also at a lower level by
dying cells [13]. Thus the detectable sHsp70 in the serum
or plasma might be composed of two different sources.
Other laboratories reported on increased levels of circulat-
ing sHsp70 up to several days after whole-body irradiation
of mice bearing xenograft prostate tumors [19] that might
be explained by dying cells. The slight increase in sHsp70
levels after radiation therapy might account for sHsp70
which is released by dying cells. Apart from dying cells vi-
able tumor cells actively secrete large amounts of Hsp70
in vesicles. In order to evaluate the amount sHsp70, serum
samples were derived of patients with SCCHN before start
of any therapy. 18 out of 21 tumor patients showed sig-
nificantly elevated sHsp70 levels in sera compared to
healthy control subjects (Figure 1). We further could
show that sHsp70 protein but not anti-Hsp70 antibody
levels could be associated with the tumor volume in
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Figure 6 NK cell activatory markers on peripheral blood
lymphocytes (PBL) of SCCHN patients before and at indicated
time-points after therapy. EDTA blood samples from selected
patients (n = 7) were collected at indicated time points before
therapy (1), after tumor resection before start of radiation therapy
(2), in the 1st year of follow-up (3), and in the 2nd year of follow-up
(4). The time points of surgery and radiation are indicated with S
and R in the upper part of each graph. NK cells were stained by
using the lysis-wash method and analyzed by flow cytometry. A-F.
CD56-positive and CD3-negative NK cells were gated and analyzed.
Mean fluorescence intensity (mfi) of CD56, CD94, NKG2D, NKp30,
NKp44, NKp46 were determined. Time-curves are shown for individual
patients. G. Mean fluorescence intensity values of all markers of all
patients with error bars and standard deviations (n = 7). Samples were
taken before therapy (1), after tumor resection before start of radiation
therapy (2), in the 1st year of follow-up (3), and in the 2nd year of
follow-up (4) * p<0.05.
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diagnosis or clinical responses do correlate with sHsp70
levels [20].
The expression density of activatory NK cell markers
which might be affected by the presence of sHsp70 pro-
tein in the serum was determined in peripheral blood
lymphocytes of SCCHN patients before, during and after
therapy. In recent studies we could show that especially
the expression density of CD94 and NKG2D were found
to be up-regulated upon stimulation with Hsp70 protein
[21]. Herein, we could show that in all patients exhibit-
ing sHsp70 the expression of NKG2D was significantly
found to be up-regulated over time (Figure 6G). Future
analysis will clarify whether the sHsp70 levels before
therapy or changes of sHsp70 levels that are induced by
therapy might be responsible for the increased expres-
sion of NKG2D on NK cells.
In summary, our data provide evidence that elevated
sHsp70 protein levels in the blood of tumor patients are
associated with the presence of primary malignant tu-
mors in SCCHN patients. Furthermore, increased sHsp70
levels were found to be associated with increased tumor
volumes. Since sHsp70 levels dropped in patients after
removal of the tumor, we speculate that sHsp70 levels
in the blood of patients might be useful not only for
the detection of tumors but also for the monitoring of
the therapeutic response to radiation therapy. Due to
the finding that mHsp70 is associated with the capacity
of tumor cells to actively release Hsp70 and due to
the fact that mHsp70 positivity was determined on a
broad variety of tumor entities such as colorectal, lung,
pancreatic and prostate cancer [16,22-24], we assume
that sHsp70 is also present in the serum of patients
with other tumor entities. Future studies in larger co-
horts and longer follow-up periods are necessary to
determine the role of sHsp70 levels as a universal tumor
biomarker.
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